Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0012833 (dizziness)
 9,689 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 4-week parallel-group, double-blind comparison of isoxicam 200 mg once daily and naproxen 250 mg 3 times daily was carried out on 30 patients with classic or definite rheumatoid arthritis. Fifteen patients were randomly assigned to each treatment group. The articular index, scoring on a pain scale and morning stiffness were significantly reduced after 2 and 4 weeks of treatment with both drugs. Grip strength was significantly increased after 4 weeks of naproxen treatment. The mean increase in grip strength was also comparable in isoxicam-treated patients, but did not reach statistical significance. Joint swelling and walking times showed improvement in both groups. One patient withdrew from isoxicam treatment with a pruritic rash considered to be drug-related and another stopped taking isoxicam because of dizziness, nausea and vomiting--also probably drug-related. Eight other patients, 4 treated with isoxicam and 4 with naproxen, reported adverse reactions associated with the digestive system. In this study isoxicam 200 mg taken once daily was similar in efficacy to and was associated with a similar incidence of adverse reactions as naproxen 250 mg taken 3 times daily. Both drugs were effective in the treatment of rheumatoid arthritis and were well tolerated.
 ...
PMID:A comparative study of isoxicam and naproxen in rheumatoid arthritis. 388 24

The efficacy and safety of minocycline was investigated in Japanese patients with rheumatoid arthritis (RA) who had already received more than three disease modifying anti-rheumatic drugs (DMARDs). Minocycline was administered at 100 mg twice a day to fifteen patients with active RA. The drug efficacy was evaluated by the clinical variables including the number of painful and/or swollen joints, the duration of morning stiffness, grip strength, the erythrocyte sedimentation rate, serum concentrations of C-reactive protein, and the titer of rheumatoid factor. Three patients experienced adverse effects such as dizziness and abdominal pain or discomfort, but only one patient with abdominal pain and dizziness was discontinued. Fourteen RA patients, who had taken minocycline for at least 6 months, were subjected to the clinical evaluation. Among them, 8 patients (54%) showed a significant improvement of clinical valuables for disease activity, beginning even at 4 weeks of the therapy. The continued effects were observed in 8 patients with over 1 year-minocycline therapy. Intriguingly, an active patient with a history of multiple DMARDs-resistancy showed a marked favorable response to this drug. The present study indicates that minocycline may be an effective DMARD with highly safe performance for patients with active and refractory RA. This is the first demonstration of the benefit of minocycline in the Japanese patients.
 ...
PMID:[An evaluation of efficacy of minocycline as an anti-rheumatic drug in patients with active and refractory rheumatoid arthritis]. 1004 18

Sulfasalazine (salazosulfapyridine) [Azulfidine, Salazopyrin] is a well established disease-modifying antirheumatic drug (DMARD) used in the treatment of patients with rheumatoid arthritis. Clinical trials with sulfasalazine have used an array of measures of disease activity, such as the number of tender and swollen joints, Ritchie articular index (RAI) and erythrocyte sedimentation rate (ESR). In randomised, double-blind, placebo-controlled trials, sulfasalazine was associated with statistically significant benefits for various measures of disease activity, according to results of individual trials and/or meta-analysis. Sulfasalazine was associated with broadly similar efficacy to that of various other DMARDs in several randomised, double-blind, comparative trials. Promising results have also been demonstrated with sulfasalazine in combination with other DMARDs (e.g. methotrexate and hydroxychloroquine) in patients with early rheumatoid arthritis and in those with more established disease. Sulfasalazine was generally well tolerated in clinical trials, the most frequently reported adverse effects being adverse gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Sulfasalazine has a relatively short lag time until its onset of action and is often considered to be among the more efficacious traditional DMARDs. Based on considerations of safety, convenience and cost, many rheumatologists (particularly outside of the US) select sulfasalazine as initial therapy, although preferred first-line treatment options vary between countries.
 ...
PMID:Sulfasalazine: a review of its use in the management of rheumatoid arthritis. 1611 81